GSK3

Glycogen synthase kinase 3: a drug target for CNS therapies.
[15189333] J Neurochem 89(6): 1313-7 (2004)

Glycogen synthase kinase 3: more than a namesake.
[19366350] Br J Pharmacol 156(6): 885-98 (2009)

Regulation of protein stability by GSK3 mediated phosphorylation.
[19923896] Cell Cycle 8(24): 4032-9 (2009)

GSK-3beta, a therapeutic target for cardiomyocyte protection.
[19506320] Circ J 73(7): 1184-92 (2009)

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.
[12039794] Circ Res 90(10): 1055-63 (2002)

Role of glycogen synthase kinase-3beta in cardioprotection.
[19498210] Circ Res 104(11): 1240-52 (2009)

GSK-3: tricks of the trade for a multi-tasking kinase.
[12615961] J Cell Sci 116(Pt 7): 1175-86 (2003)

Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development.
[19064989] J Biol Chem 284(15): 9643-7 (2009)

Significance of SGK1 in the regulation of neuronal function.
[20530112] J Physiol 588(Pt 18): 3349-54 (2010)

Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs.
[19179804] J Pharmacol Sci 109(2): 179-83 (2009)

Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury.
[19179805] J Pharmacol Sci 109(2): 162-7 (2009)

Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: targeting the Wnt pathway and transplantation therapy as strategies for retinal repair.
[19179807] J Pharmacol Sci 109(2): 168-73 (2009)

Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
[19423950] J Pharmacol Sci 110(1): 14-28 (2009)

GSK3beta: role in therapeutic landscape and development of modulators.
[20331603] Br J Pharmacol 160(1): 1-19 (2010)

Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
[18204489] Br J Pharmacol 153 Suppl 1(-): S137-53 (2008)

GSK3: a multifaceted kinase in Wnt signaling.
[19884009] Trends Biochem Sci 35(3): 161-8 (2010)

mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
[15851011] Mol Ther 11(5): 724-33 (2005)

Valproate attenuates accelerated atherosclerosis in hyperglycemic apoE-deficient mice: evidence in support of a role for endoplasmic reticulum stress and glycogen synthase kinase-3 in lesion development and hepatic steatosis.
[19095952] Am J Pathol 174(1): 330-42 (2009)

Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction.
[18583310] Am J Pathol 173(2): 451-62 (2008)

Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis.
[21995961] Am J Physiol Gastrointest Liver Physiol 302(1): G77-84 (2012)

Control of tumor suppressor p53 function by endoplasmic reticulum stress.
[15107622] Cell Cycle 3(5): 567-70 (2004)

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
[15827567] Neuropsychopharmacology 30(7): 1223-37 (2005)

GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.
[17499358] Neurosci Biobehav Rev 31(6): 920-31 (2007)

Wnt signaling as a therapeutic target for bone diseases.
[19335070] Expert Opin Ther Targets 13(4): 485-96 (2009)

Brief review of the role of glycogen synthase kinase-3β in amyotrophic lateral sclerosis.
[21603026] Neurol Res Int 2011(-): 205761 (2011)

GSK-3: Functional Insights from Cell Biology and Animal Models.
[22110425] Front Mol Neurosci 4(-): 40 (2011)

GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.
[22110426] Front Mol Neurosci 4(-): 45 (2011)

Role of GSK3 Signaling in Neuronal Morphogenesis.
[22131966] Front Mol Neurosci 4(-): 48 (2011)

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.
[21886606] Front Mol Neurosci 4(-): 16 (2011)

Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies.
[22007157] Front Mol Neurosci 4(-): 24 (2011)

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.
[16944320] Neurochem Res 32(4-5): 577-95 (2007)

In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
[17572175] Biol Psychiatry 62(1): 4-6 (2007)

Targeting Glycogen Synthase Kinase-3β for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway.
[21629716] Int J Alzheimers Dis 2011(-): 985085 (2011)

Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer's disease?
[21629736] Int J Alzheimers Dis 2011(-): 129753 (2011)

Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation.
[21776376] Int J Alzheimers Dis 2011(-): 352805 (2011)

Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).
[19836308] Trends Immunol 31(1): 24-31 (2010)

The GSK-3/beta-catenin-signalling axis in smooth muscle and its relationship with remodelling.
[18612673] Naunyn Schmiedebergs Arch Pharmacol 378(2): 185-91 (2008)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\GSK3.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\GSK3.php on line 92